Figure 22
Anticipated Costs Post-Approval While neither compound has reached market, pricing for similar medications provides context: Semaglutide (Wegovy) Approximately $1,300-$1,500 monthly without insurance Tirzepatide (Zepbound) Approximately $1,000-$1,200 monthly without insurance Cagrilintide and retatrutide would likely fall in similar price ranges, with combination therapy potentially costing $2,000-$3,000 monthly without insurance coverage
We recently reviewed elsewhere the vast array of therapeutic opportunities that the targeting of each one of these receptors offers, not only as a hope for the future, but as a current success, as several MC drugs have already been approved and many others are in clinical phase of development (135)
Difficulty in Sleeping: The high energy levels created by L-carnitine can cause difficulty in sleeping for some people, though this is something that has been reported on a very mild scale
Lets be honest, the idea of sipping a fizzy drink to melt away fat sounds incredible
